HIV infects white blood cells and can hide from our immune system within them. Current therapy can target replicating virus, but does not eliminate the infected cells. These infected white blood cells are what prevent any current drugs from curing HIV infection. It has been found that efficient HIV-1 infection and spreading requires T-cells expressing LFA-1 and T-cells with activated LFA-1 are more susceptible to HIV-1 infection. Thus, HIV-infected cells are marked with higher levels of activated LFA-1, making them good targets for Leukothera™. In preclinical studies, Leukothera™ is able to deplete HIV-infected cells ex vivo from patients with active HIV infection.
Hematologic diseases (leukemia, lymphoma, and multiple myeloma) are cancers of white blood cells that are often deadly and difficult to treat. Preclinical efficacy studies have shown that Leukothera™ is highly effective at eliminating malignant white blood cells both under laboratory conditions and in animals.Read More
Autoimmune and inflammatory diseases comprise a range of disorders that are characterized by the abundant presence of chronically activated WBCs. Leukothera® specifically targets these activated WBCs without affecting healthy cells and tissues.Read More
HIV infects white blood cells and can hide from our immune system within them. Current therapies can target replicating virus, but do not eliminate the HIV-infected cells. These infected white blood cells are what prevent any current drugs from curing HIV infection.Read More